The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia

The aim of the study was to investigate any possible influence of polymorphisms of transmembrane transporters human organic cation transporter 1 (hOCT1), ABCB1, ABCG2 on imatinib pharmacokinetics in 33 men and 27 women (median age and range, 56 and 27–79 years, respectively) affected by chronic myel...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The pharmacogenomics journal 2014-08, Vol.14 (4), p.328-335
Hauptverfasser:	Di Paolo, A, Polillo, M, Capecchi, M, Cervetti, G, Baratè, C, Angelini, S, Guerrini, F, Fontanelli, G, Arici, R, Ciabatti, E, Grassi, S, Bocci, G, Hrelia, P, Danesi, R, Petrini, M, Galimberti, S
Format:	Artikel
Sprache:	eng
Schlagworte:	631/208/726/649 631/92/436/1729 631/92/436/434 692/699/67/1990/283/1896 Adult Aged Antineoplastic Agents - pharmacokinetics ATP Binding Cassette Transporter, Sub-Family B - genetics Benzamides - pharmacokinetics Benzamides - therapeutic use Biomedical and Life Sciences Biomedicine Chronic myeloid leukemia Drug metabolism Drug therapy Female Gene Expression Gene polymorphism Genetic aspects Genotype Haplotypes Human Genetics Humans Imatinib Imatinib Mesylate Inhibitor drugs Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Male Membrane proteins Metabolic Clearance Rate Middle Aged Myeloid leukemia Oncology Organic cation transporter Organic Cation Transporter 1 - genetics original-article Pharmacokinetics Pharmacotherapy Piperazines - pharmacokinetics Piperazines - therapeutic use Polymorphism, Single Nucleotide Properties Psychopharmacology Pyrimidines - pharmacokinetics Pyrimidines - therapeutic use Single-nucleotide polymorphism Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!